Polypills for the prevention of Cardiovascular diseases

References

• Cardiovascular diseases (CVDs) fact sheet N°317. Geneva: World Health Organization; 2015 [cited 2016 Mar 1].
   Google Scholar
• Global action plan for the prevention and control of noncommunicable diseases 2013-2020. 2013 [cited 2016 Mar 1]. World Health Organization. ISBN 978 92 4 150623 6
   Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
   PubMed Web of Science ®Google Scholar
• WHO-Wellcome Trust Meeting on Secondary Prevention, World Health Organization, Wellcome Trust (London). Secondary prevention of noncommunicable diseases in low- and middle-income countries through community-based and health service interventions: World Health Organization-Wellcome Trust meeting report, 1-3 August 2001. 2002 [cited 2016 Mar 1]. Geneva: World Health Organization.
   Google Scholar
• Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2–3.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373:1341–1351.
   PubMed Web of Science ®Google Scholar
• Neutel JM, Bestermann WH, Dyess EM, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2009;11:22–30.
   PubMed Web of Science ®Google Scholar
• Grimm R, Malik M, Yunis C, et al. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc Health Risk Manag. 2010;6:261–271.
   PubMedGoogle Scholar
• Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. Int J Clin Pract. 2010;64:1220–1227.
   PubMed Web of Science ®Google Scholar
• Rodgers A, Patel A, Berwanger O, et al. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One. 2011;6:e19857.
   PubMed Web of Science ®Google Scholar
• Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011;27:821–833.
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Mendis S, Dissanayake WP, et al. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials. 2011;12:3.
   PubMed Web of Science ®Google Scholar
• Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7:e41297.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032–2043.
   PubMed Web of Science ®Google Scholar
• The International Polycap Study 3 (TIPS-3) NCT01646437. ClinicalTrials.gov. 5-22-2015. 2016 Mar 1.
   Google Scholar
• Ostovaneh MR, Poustchi H, Hemming K, et al. Polypill for the prevention of cardiovascular disease (polyIran): study design and rationale for a pragmatic cluster randomized controlled trial. Eur J Prev Cardiol. 2015;22:1609–1617.
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention and Evaluation 4 (HOPE-4) NCT01826019. ClinicalTrials.gov. 2-26-2016. 2016 Mar 1.
   Google Scholar
• Yusuf S, Pais P, Sigamani A, et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the second indian polycap study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes. 2012;5:463–471.
   PubMed Web of Science ®Google Scholar
• Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918–929.
   PubMed Web of Science ®Google Scholar
• Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22:920–930.
   PubMed Web of Science ®Google Scholar
• Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64:2071–2082.
   PubMed Web of Science ®Google Scholar
• Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318.
   PubMed Web of Science ®Google Scholar
• Fuster V, Sanz G. A polypill for secondary prevention: time to move from intellectual debate to action. Nat Clin Pract Cardiovasc Med. 2007;4:173.
   PubMedGoogle Scholar
• Webster R, Patel A, Selak V, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. 2016;205:147–156.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Castellano JM, Fuster V. The fuster-CNIC-ferrer cardiovascular polypill: a polypill for secondary cardiovascular prevention. Int J Cardiol. 2015;201(Suppl 1):S15–S22.
   Google Scholar
• Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368:679–686.
   PubMed Web of Science ®Google Scholar
• van Gils PF, Over EA, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011;1:e000363.
   PubMed Web of Science ®Google Scholar
• Becerra V, Gracia A, Desai K, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015;5:e007111.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Luteijn JM, Morris JK, et al. Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke. Eur J Epidemiol. 2016;31:415–426.
   PubMed Web of Science ®Google Scholar
• Frye JE, editor. International drug price indicator guide, 2014. Medford (MA): Management Sciences for Health; [2014] 2015 [cited 2016 Jun 25].
   Google Scholar
• Huffman MD, Mendis S, Fuster V, et al. An application to recommend that fixed dose combination therapy be added to the WHO model list of essential medicines for secondary prevention of cardiovascular disease (ischemic heart disease and thrombotic stroke). World Health Organization. 2012 [cited 2016 Jun 25].
   Google Scholar
• Smith R, McCready T, Yusuf S. Combination therapy to prevent cardiovascular disease: slow progress. JAMA. 2013;309:1595–1596.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Attaran A, Bosch J, et al. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J. 2014;35:353–364.
   PubMed Web of Science ®Google Scholar
• Selak V, Bullen C, Stepien S, et al. Do polypills lead to neglect of lifestyle risk factors? findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. Eur J Prev Cardiol. 2016;23:1393–1400.
   PubMed Web of Science ®Google Scholar
• Viera AJ. The polypill to prevent cardiovascular disease: physicians’ perspectives. Curr Opin Cardiol. 2011;26:438–442.
   PubMed Web of Science ®Google Scholar
• Holt S. New Zealand general practitioners’ opinions of the polypill concept. N Z Med J. 2009;122:116–117.
   PubMedGoogle Scholar
• Virdee SK, Greenfield SM, Fletcher K, et al. Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? a qualitative interview study. BMJ Open. 2013;3:e002498.
   Web of Science ®Google Scholar
• Elley CR, Gupta AK, Webster R, et al. The efficacy and tolerability of ‘polypills’: meta-analysis of randomised controlled trials. PLoS One. 2012;7:e52145.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. position paper from an international lipid expert panel. Arch Med Sci. 2015;11:1–23.
   PubMed Web of Science ®Google Scholar
• Banach M, Aronow WS. Hypertension therapy in the older adults-do we know the answers to all the questions? the status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens. 2012;26:641–643.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol 2014. 2013;63:2889–2934.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Gheorghiade M, Butler J. Expanding the scope of the “polypill” to heart failure. J Card Fail. 2013;19:540–541 .
   PubMed Web of Science ®Google Scholar